Use of BRAF inhibitors in pediatric brain cancers has been reported in a case report of pediatric brain stem ganglioglioma with a BRAF V600E mutation, where the patient was successfully treated with vemurafenib and vinblastine [22]. The gene discussed is BRAF; the disease is brain cancer.